Gene Expression in Peripheral Blood Leukocytes in Monozygotic Twins Discordant for Chronic Fatigue: No Evidence of a Biomarker by Byrnes, Andrea et al.
Gene Expression in Peripheral Blood Leukocytes in
Monozygotic Twins Discordant for Chronic Fatigue: No
Evidence of a Biomarker
Andrea Byrnes
1,2, Andreas Jacks
3, Karin Dahlman-Wright
4, Birgitta Evengard
5, Fred A. Wright
2, Nancy L.
Pedersen
3*, Patrick F. Sullivan
1,3*
1Department of Genetics, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America, 2Department of Biostatistics, University of North
Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America, 3Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm,
Sweden, 4Department of Biosciences and Nutrition, Karolinska Institutet, Stockholm, Sweden, 5Department of Clinical Microbiology, University of Umea ˚, Umea ˚, Sweden
Abstract
Background: Chronic fatiguing illness remains a poorly understood syndrome of unknown pathogenesis. We attempted to
identify biomarkers for chronic fatiguing illness using microarrays to query the transcriptome in peripheral blood leukocytes.
Methods: Cases were 44 individuals who were clinically evaluated and found to meet standard international criteria for
chronic fatigue syndrome or idiopathic chronic fatigue, and controls were their monozygotic co-twins who were clinically
evaluated and never had even one month of impairing fatigue. Biological sampling conditions were standardized and RNA
stabilizing media were used. These methodological features provide rigorous control for bias resulting from case-control
mismatched ancestry and experimental error. Individual gene expression profiles were assessed using Affymetrix Human
Genome U133 Plus 2.0 arrays.
Findings: There were no significant differences in gene expression for any transcript.
Conclusions: Contrary to our expectations, we were unable to identify a biomarker for chronic fatiguing illness in the
transcriptome of peripheral blood leukocytes suggesting that positive findings in prior studies may have resulted from
experimental bias.
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Introduction
Theetiologyofchronicfatiguesyndrome(CFS)isunknown[1–3].
Many theories of the pathophysiology of CFS have been suggested
[4–9], often based on suspicions of the role of an acute viral illness or
immune dysfunction. The availability of a biomarker for CFS would
be of particular benefit for clinical and basic research.
Gene expression studies of peripheral blood leukocytes (PBLs) are
a potentially promising source of biomarkers for CFS [10]. PBLs are
both accessible and salientfor CFS given theprominenceofimmune
and infectious theories of its etiology. Moreover, gene expression
patterns in human PBLs are not unrelated to less accessible tissues
like brain [11]. We are aware of four published non-overlapping
studies that compared gene expression in PBLs in cases with CFS in
comparison to controls [12–15]. These small studies included a total
of only 45 cases (5, 7, 8, and 25) and, of the 108 transcripts reported
to have altered expression, only one transcript was altered in more
than one study (MSN, moesin). [13,15]
Given the lack of clarity in existing studies of CFS, we
undertook an ‘‘unbiased’’, transcriptome-wide search for gene
expression changes associated with CFS in PBLs. Our study had
two notable design features. First, we used a control group optimal
for detecting state-related gene expression changes and minimized
false-positive findings due to genetic mismatching between cases
and controls as we contrasted 44 individuals with clinically-
evaluated chronic fatiguing illness with their 44 unaffected
monozygotic co-twins. Use of rigorously discordant monozygotic
twins provides the best control for genetic background currently
possible in humans and allows use of paired statistics with greater
statistical power. Second, we carefully standardized sampling
conditions so that PBL samples were drawn into RNA-stabilizing
media and taken from both members of a twin pair at the same
time and place.
Materials and Methods
Ethics Statement
The protocol was approved in advance by the ethical review
board at UNC-CH and the Karolinska Institutet and all subjects
provided written informed consent.
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Registry for the symptoms of fatiguing illness [16–18]. All twins
were born in Sweden of Scandinavian ancestry. Of 5,597
monozygotic twin pairs where both were alive and had provided
usable responses to CFS screening questions, we identified 140
pairs of twins who met preliminary inclusion criteria: born 1935–
1985, classified as a monozygotic twin based on questionnaire
responses [19], and discordant for chronic fatiguing illness (i.e.,
one twin reported substantial fatigue and the other twin was
evidently well). A telephone interview using a standardized script
was used to assess eligibility for participation. Twins who remained
eligible attended a half-day clinical assessment by a specially
trained physician at the Karolinska Institutet in Stockholm. At this
visit, a CFS-focused medical assessment was conducted that
included standardized medical history, physical examination, and
screening biochemical, hormonal, and hematological studies in
accordance with international recommendations [1].
Of 140 monozygotic and preliminarily discordant twin pairs,
one or both twins declined participation in 23 pairs, 25 pairs were
concordant for CFS-like illness, and inclusion criteria were not met
in 35 pairs (e.g., chronic fatigue had resolved or an illness that
could explain fatiguing symptoms such as neoplasia had emerged).
After excluding these 83 pairs, 57 pairs of twins attended the
clinical evaluation sessions, and 10 pairs were found not to meet
inclusion criteria (9 pairs were concordant for the presence or
absence of chronic fatigue or a medical explanation was detected –
e.g., newly diagnosed type 2 diabetes mellitus – and 1 pair was
dizygotic). Zygosity was confirmed by genotyping 46 single
nucleotide polymorphisms using two Sequenom iPlex panels. In
3 pairs, microarray data of satisfactory quality could not be
obtained.
The analysis sample consisted of 44 pairs of rigorously
discordant and genetically proven monozygotic twins. Discor-
dance was defined as one twin meeting criteria for either
idiopathic chronic fatigue (ICF, 12 pairs) or CFS (32 pairs) [1,2]
and the co-twin was required never to have experienced impairing
unusual fatigue or tiredness lasting more than one month. Thus,
all affected twins were required to have current, long-standing ($6
months), medically unexplained fatigue associated with substantial
impairment in social and occupational functioning and the
unaffected co-twins were effectively well. A diagnosis of CFS adds
a requirement for $4 of 8 specific symptoms (e.g., unrefreshing
sleep, muscle pain) to that of ICF. We explain elsewhere the
rationale for including ICF along with CFS based on phenotypic
[17] and twin analyses [18].
Transient/situational factors can influence gene expression
measurements. Biological sampling was standardized by having
samples drawn from both members of a twin pair at the same
place and time (,0900) after an overnight fast. We required that
all subjects be in their usual state of health on the day of sampling
(i.e., no acute illness or recent exacerbation of a chronic illness). It
was neither practical nor ethical to study subjects medication-free,
but we delayed assessment if there had been a recent significant
dosage change.
Peripheral venous blood was drawn using sterile technique into
PAXgene tubes manufactured in the same batch (Qiagen, to
protect RNA from degradation and to minimize ex vivo gene
expression). Total RNA was purified using the PAXgene blood
RNA kit following the manufacturer’s instructions (Qiagen). RNA
quality was determined using the Agilent 2100 Bioanalyzer. Total
RNA (5.0 mg) was labeled with the one-cycle cDNA synthesis kit
(Invitrogen) and spiked with eukaryotic Poly-A RNA controls to
check the target labeling process (Affymetrix). Synthesized cDNA
was transcribed in vitro using the GeneChip IVT labeling kit
(Affymetrix). The biotin labeled cRNA product (20 mg) was
purified with a sample cleanup module (Qiagen) and samples
were fragmented with the fragmentation buffer from Affymetrix at
94uC for 35 minutes. Fragmented and labeled targets (together
with hybridization and oligo B2 controls) were hybridized to
Affymetrix Human Genome U133 Plus 2.0 arrays at 45uC for
16 hours. Washing and staining of the arrays were performed on
the Affymetrix fluidics station using the EukGE-WS2v5_450
protocol. Imaging of the arrays and signal quantification were
performed with the Affymetrix GeneChip Scanner 3000 and
GeneChip Operating Software. For verification, we used qRT-
PCR. RNA was converted to cDNA with Superscript III
(Invitrogen) and qRT-PCR was run with ABI’s Taqman gene
expression assays (with 18S rRNA as control). The DDCt method
was used for the calculations.
Array images were manually checked for defects using DChip
[20,21] and then normalized using the RMA algorithm in
Affymetrix Expression Console (v1.0). After normalization, the
Bioconductor [22] Significance Analysis of Microarrays package
[23] was used to compute modified paired t-tests that contrasted
an affected twin with the unaffected co-twin for each transcript
using R [24]. To adjust for multiple comparisons, the nominal
permutation-based p-values from SAM were used to compute false
discovery rate q-values [25–27]. Pathway analyses for KEGG
pathways [28], GO keywords [29] (biological process, cellular
component, and molecular function), and PFAM protein family
groupings [30] were conducted using SAFE which performs array
permutation to account for transcript correlation [31,32]. These
expression data are available from GEO (http://www.ncbi.nlm.
nih.gov/geo) under accession number GSE16059 and were
prepared in accordance with MIAME 2.0 standards.
Results
The analytic data set consisted of microarray data from 44 pairs
of monozygotic twins discordant for clinically-evaluated chronic
fatiguing illness (Table 1). Most pairs were female (89%), and the
median age at evaluation was 51 years. Of the affected twins, 32
met criteria for CFS and 12 for ICF with a median duration of
chronic fatigue of 8 years with no significant difference between
affected twins with CFS and ICF (paired t43=0.32, p=0.75).
Body mass index was similar between the affected and unaffected
twins. Two affected individuals (4.5%) reported sudden onset of
fatigue. Affected twins had significantly worse physical and mental
functioning on the SF-36 [33] and reported significantly greater
current fatigue. The mean functioning of affected twins was over a
standard deviation worse than Swedish norms whereas the
unaffected twins were similar to Swedish norms (http://www.sf-
36.org/nbscalc/index.shtml, accessed 12 December 2008).
The main analyses contrasted gene expression in PBLs in 44
pairs of monozygotic twins affected with CFS or ICF to that of
their unaffected co-twins. As inclusion of males could increase
noise, the second planned analysis compared 39 female pairs with
CFS or ICF and the third planned analysis compared the 28 pairs
of female twins with CFS. For each of these three sets of statistical
comparisons, the observed results did not deviate from those
expected by chance (Figure S1). When we compared our findings
to a list of 108 transcripts reported as differentially expressed in
CFS [12–15], 107 were studied in our experiment, 101/107 had
p.0.1 in our study, and only two had p,0.05 (CXCR4 p=0.03
and RAP2C p=0.04), a degree of overlap that does not depart
from chance expectations. At the single transcript level, there was
no biological evidence of altered gene expression in PBLs that
correlated with chronic, impairing, and medically unexplained
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expression of seven genes selected from the CFS gene expression
literature and our empirical findings (ANKLE2, BLKE, BRD1,
CPA3, DCTN1, ICAM, and ORC). All p-values from paired t-tests
contrasting affected and unaffected monozygotic twins were
$0.26.
It is possible that functionally-related genes might have
important set-wise gene expression changes with no individual
transcript meeting criteria for significance. As a hypothesis-
generating analysis, we used SAFE [31] to conduct analyses of
gene groupings defined by KEGG pathways [28], GO keywords
[29] (biological process, cellular component, and molecular
function), and PFAM protein family groupings [30]. Broadly,
these analyses revealed significant differences in cell replication
processes and amino acid and lipid metabolic pathways (Table
S1). These results do not map directly onto current major theories
of CFS pathogenesis and should be regarded as hypothesis-
generating.
Discussion
Main Finding
The overarching goal in this study was to attempt to identify one
or more biomarkers for chronic fatiguing illness via a compre-
hensive search of the ‘‘transcriptome’’ in an accessible tissue
(peripheral blood leukocytes, PBLs) plausibly involved in the
pathophysiology of this idiopathic syndrome. We attempted to
correct methodological issues in prior reports by careful control of
sources of bias (e.g., by studying discordant monozygotic twin
pairs, use of RNA stabilizing media, and standardized sampling
conditions). We found no evidence of differential PBL gene
expression that characterized the presence or absence of CFS or
ICF. Therefore, unlike most prior published studies, we did not
find evidence of a gene expression biomarker for chronic fatiguing
illness.
Methodological Issue: genetic matching in gene
expression studies
These results may hold a lesson for case-control gene expression
studies in humans. There are certainly examples where transcrip-
tomic studies have yielded results that have the potential to
improve disease prognosis and management (e.g., breast cancer)
[34]; however, gene expression studies have the potential to yield
false positive findings if the ancestry of cases and controls are not
appropriately matched. Genetic background is usually not taken
into consideration although gene expression is can be both
heritable and under strong genetic control [35]. Relatively low-
resolution studies in immortalized PBLs suggest that hundreds of
human genes are under relatively strong genetic control by
common genetic variants (e.g., the single nucleotide polymor-
phism ‘‘rs407257’’ is strongly associated (p,10
266)w i t ht h e
expression level of glutathione S-transferase theta 1, GSTT1)
[36]. The genetic variant rs407257 is variable in human
populations (allele frequencies of 0.72, 0.64, and 0.39 in African,
East Asian, and European samples) [37]. If case and control
subjects are not extremely well-matched for genetic background
(including for location within Europe) highly significant differ-
ences could occur because of bias from inappropriate case-
control matching. This concern is particularly important for
studies of PBLs as genes whose expression is under strong
genetic control [36] are highly enriched for genes expressed in
lymphoid tissue and lymphocyte cell populations (analyses using
DAVID [38], data not shown).
Use of discordant monozygotic twins represents the best control
for genetic background currently possible in humans. Assuming
identify at the DNA level and control for experimental bias, gene
expression differences in discordant monozygotic twins can be
cleanly attributed to disease state. It is reasonable to consider if use
of discordant monozygotic twins represents ‘‘over-matching’’. In
comparisons of unrelated cases and controls, gene expression
differences are an amalgam of disease state, the RNA-level impact
of genetic loci causal to the trait, and the effects of case-control
genetic mismatching (i.e., non-causal loci that differ in frequency
between cases and controls and which have strong control on gene
expression). Use of discordant monozygotic twins yields more
interpretable results particularly as there are large numbers of non-
causal loci under genetic control. We would also argue that a gene
expression study is a poor way to identify genetic loci causal to a
disease when an alternative study design (the genome-wide
association study) has been so successful [39].
Conclusions
We were unable to identify a biomarker for chronic fatiguing
illness in the transcriptome of peripheral blood leukocytes
suggesting that positive findings in prior studies may have resulted
from experimental bias.
Table 1. Descriptive characteristics for 44 pairs of monozygotic twins discordant for chronic fatiguing illness.
Variable Affected twins Unaffected co-twins Statistical comparison
Met criteria for CFS 32/44, 73% 0/44, 0% By design
Met criteria for ICF 12/44, 27% 0/44, 0% By design
Female sex 39/44, 89% 39/44, 89% Identical by design
Median age at evaluation, IQR 51, 39–59 years 51, 39–59 years Identical by design
Median body mass index, IQR 24.6, 22–30 kg/m
2 24.4, 22–31 kg/m
2 Paired t43=0.2, p=0.87
Median SF-36 physical function, IQR 41.2, 28–48 48.2, 40–52 Paired t43=3.0, p=0.004
Median SF-36 mental function, IQR 38.9, 29–47 51.6, 40–56 Paired t43=5.0,p=1 610
25
Median current fatigue by VAS, IQR 69, 49–77 19, 10–51 Paired t43=27.2, p=6610
29
Median duration of fatigue, IQR 7.6, 4–16 years NA –
Sudden onset of fatigue 2/44, 4.5% NA –
Abbreviations. CFS=chronic fatigue syndrome, ICF=idiopathic chronic fatigue, IQR=inter-quartile range, VAS=visual analog scale (0–100, higher means greater
fatigue at clinical examination).
doi:10.1371/journal.pone.0005805.t001
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Table S1 Shown are results from pathway analyses using SAFE
to investigate KEGG pathways, GO keywords (BP=biological
process, CC=cellular component, and MF=molecular function),
and PFAM protein family groupings. These all had an empirical p-
value (from permutation) ,0.005 and were composed of $10
transcripts.
Found at: doi:10.1371/journal.pone.0005805.s001 (0.11 MB
DOC)
Figure S1 Quantile-quantile (QQ) plots from the planned paired
analyses contrasting monozygotic (MZ) twins affected with chronic
fatiguing illness versus their unaffected co-twins. CFS=chronic
fatigue syndrome, ICF=idiopathic chronic fatigue. The observed
distribution of statistical results conform to chance expectations.
Found at: doi:10.1371/journal.pone.0005805.s002 (0.11 MB
DOC)
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